Skip to main content

CRISPR Therapeutics AG (CRSP)

NASDAQ: CRSP · IEX Real-Time Price · USD
95.25
-0.31 (-0.32%)
After-hours:Oct 22, 2021 7:59 PM EDT
95.56
-1.50 (-1.55%)
At close: Oct 22, 4:00 PM
Market Cap7.40B
Revenue (ttm)901.76M
Net Income (ttm)446.58M
Shares Out76.20M
EPS (ttm)5.90
PE Ratio16.19
Forward PE23.36
Dividendn/a
Ex-Dividend Daten/a
Volume1,325,471
Open96.95
Previous Close97.06
Day's Range94.25 - 97.65
52-Week Range84.38 - 220.20
Beta2.25
AnalystsBuy
Price Target159.05 (+66.4%)
Est. Earnings DateOct 28, 2021

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate...

IndustryBiotechnology
IPO DateOct 19, 2016
CEOSamarth Kulkarni
Employees410
Stock ExchangeNASDAQ
Ticker SymbolCRSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 159.05, which is an increase of 66.44% from the latest price.

Price Target
$159.05
(66.44% upside)
Analyst Consensus: Buy

News

Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to Decline

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

3 Things About CRISPR Therapeutics That Smart Investors Know

The company's value isn't reflected in typical performance metrics.

3 days ago - The Motley Fool

3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket

These growth stocks could rebound in a big way.

Other symbols:ARCTTDOC
4 days ago - The Motley Fool

2 Top Healthcare Stocks That Could Be Bought Out in 2022

These two novel-drug makers could be top takeover targets next year.

Other symbols:ADAP
1 week ago - The Motley Fool

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Other symbols:BEAMEDITSRPT
1 week ago - Zacks Investment Research

CRISPR Therapeutics Announces Transition of Chief Financial Officer

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serio...

1 week ago - GlobeNewsWire

CRISPR price outlook: RBC sees upside to $117

Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) fell just under 10% on Wednesday as the biotech firm presented updated data for the phase 1 trial of its blood cancer candidate CTX 110.  RBC Capital main...

1 week ago - Invezz

CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today

Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower ...

1 week ago - InvestorPlace

Why CRISPR Therapeutics Stock Is Sinking Today

Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.

1 week ago - The Motley Fool

Why CRISPR Therapeutics Stock Is Tumbling Today

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies. “We are e...

1 week ago - Benzinga

Will CRISPR Stock Rebound After A 17% Fall In A Month?

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year befor...

1 week ago - Forbes

How to Invest in Biotech Stocks in a Bear Market

Hint: it doesn't really matter what kind of market it is.

Other symbols:CPRXVCEL
1 week ago - The Motley Fool

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+...

-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-

1 week ago - GlobeNewsWire

Why CRISPR Therapeutics (CRSP) Stock is Falling Today

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

2 weeks ago - Zacks Investment Research

Why CRISPR Therapeutics Stock Fell 10.4% Last Month

CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.

2 weeks ago - The Motley Fool

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-

2 weeks ago - GlobeNewsWire

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.

3 weeks ago - Zacks Investment Research

3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.

Other symbols:BCRXVRTX
3 weeks ago - The Motley Fool

4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years

These companies could deliver jaw-dropping revenue growth through mid-decade.

Other symbols:NKLAOCGNVXRT
3 weeks ago - The Motley Fool

Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate

Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-relate...

Other symbols:EDIT
3 weeks ago - Benzinga

These 3 Top Healthcare Stocks Are Screaming Buys Right Now

If the market crashes these companies could be insulated.

Other symbols:BMYFLGT
3 weeks ago - The Motley Fool

7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio

These top seven stocks among Cathie Wood's top holdings are ones investors may be enticed to consider right now. The post 7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio appeared fir...

3 weeks ago - InvestorPlace

CRISPR Therapeutics to Participate in the Chardan's 5th Annual Genetic Medicines Conference

ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

3 weeks ago - GlobeNewsWire

Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another

Wood is following an important strategy with gene-editing stocks.

Other symbols:BEAMEDITVRTX
1 month ago - The Motley Fool

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.

1 month ago - Zacks Investment Research